CBDMD INC (YCBD)
AMEXHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
$0.39-4.43%
Close 2026-11-05 · 1-day change
AMEXHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
QuarterlyIQ Insights · YCBD
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
ex_1036979.htm Exhibit 99.1 cbdMD Completes Acquisition of the Operating Assets and Brands of Twinlab, including Twinlab, Reserveage and Metabolife Brands, Expanding Into Broader Wellness Iconic supp…
Stated in a supplied disclosure. Management reported: “Based on unaudited financial information, the combined unaudited trailing twelve months of revenue ending June 2026 totals approximately $30 million, which would represent an increase of approximately 40% relative to cbdMD’s standalone revenue for the same period.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
The acquired brands operate outside the hemp category, reducing the Company's exposure to changes in federal and state hemp regulation.
Stated in a supplied disclosure. Management reported: “This transaction is expected to reduce cbdMD’s revenue concentration in the hemp category and mitigate risks associated with the evolving regulatory environment for hemp-derived products.” “The acquired brands operate outside the hemp category, reducing the Company's exposure to changes in federal and state hemp regulation.”
cbdMD's in-house creative and performance marketing team, which has built and repositioned consumer brands across retail and e-commerce, will now support them.
Stated in a supplied disclosure. Management reported: “We believe there is a significant opportunity to build on cbdMD’s revenue growth by applying our marketing, creative, and ecommerce resources to drive brand awareness and expand direct-to-consumer sales, alongside the strong wholesale and retail presence these brands already have.” “cbdMD's in-house creative and performance marketing team, which has built and repositioned consumer brands across retail and e-commerce, will now support them.”
Maintain operational stability by extending the lease of the warehouse and executive offices in Charlotte, North Carolina.
Navigate capital allocation challenges following new financial obligations, including those related to acquisitions and lease amendments.
Over the trailing year it converted 0.11x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
16 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.